immunotherapy
Lifileucel / TIL therapy
FDA accelerated approval exists for a specific adult unresectable or metastatic melanoma context after prior PD-1 therapy, and if BRAF V600 positive, after BRAF therapy with or without a MEK inhibitor.
Approved in some placesBRAF context matters for prior therapymutation-agnosticUnited States
What this is
TIL therapy is different from ordinary checkpoint immunotherapy. A tumor sample is used to grow a patient's own immune cells outside the body, then the cells are given back through a specialized treatment program.
Why it may come up
- Melanoma is unresectable or metastatic.
- Prior PD-1 therapy has already been used.
- A family is asking what options commonly come up after immunotherapy stops working.
What not to assume
- It does not mean every patient after PD-1 therapy can receive TIL therapy.
- It does not mean it is available in every country or hospital.
- It does not replace the need for a trial and referral timing conversation.
- Evidence level
- approved-jurisdiction-specific
- Where
- United States
- Mutation result
- BRAF context matters for prior therapy, mutation-agnostic
- Last checked
- 2026-05-21
- Review status
- source backed page
Plain-English summary
TIL therapy is different from ordinary checkpoint immunotherapy. A tumor sample is used to grow a patient's own immune cells outside the body, then the cells are given back through a specialized treatment program.
What the sources say
- FDA granted accelerated approval to lifileucel for adult unresectable or metastatic melanoma after prior PD-1 blocking antibody, with an additional BRAF-targeted prior-therapy condition when BRAF V600 is positive.
- NCI lists lifileucel among FDA-approved melanoma drugs.
- This is a specialized cell-therapy pathway, so practical access depends on treatment center, timing, disease status, and country.
When this commonly comes up
- Melanoma is unresectable or metastatic.
- Prior PD-1 therapy has already been used.
- A family is asking what options commonly come up after immunotherapy stops working.
- The care team is considering referral to a specialized melanoma or cell-therapy center.
What this does not mean
- It does not mean every patient after PD-1 therapy can receive TIL therapy.
- It does not mean it is available in every country or hospital.
- It does not replace the need for a trial and referral timing conversation.
Important cautions
- Accelerated approval means the FDA approval was based on a specific evidence pathway and context.
- TIL therapy can require complex logistics, tumor collection, cell manufacturing, and specialized-center coordination.
- Ask early whether starting another treatment could affect timing or feasibility.
Questions to ask
- Does the FDA-labeled lifileucel context resemble this case?
- Is there a melanoma center or TIL center that should review the case?
- Would another treatment make TIL referral harder or more urgent?
- What records would a TIL center need before saying whether consultation makes sense?